Composite collagen eye drops

A technology of collagen and original protein, which is applied in the field of medical medicine, can solve the problems of short effective time of medicine, poor penetration of medicine, lack of biological activity, etc., and achieve the effect of prolonging the effective time, reducing visual fatigue and keeping eyeballs moist

Active Publication Date: 2007-03-14
GUANGZHOU TRAUER BIOTECH
View PDF0 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

Collagen eye drop products have been developed that contain certain substances like bacitracin or other drugs in order to improve their efficacy against specific conditions such as inflammations caused by various factors including aging (wrinkles), blephariasis, acute pigmented skin disorders, contact lens wearers' syndrome) and diseases associated therewith. These treatments aim at reducing symptoms related to these causes while still providing some beneficial benefits over existing treatment methods.

Problems solved by technology

The technical problem addressed by this patented technology relates to improving the efficiency or reducing side effects associated with administered drugs for treatments such as ocular inflammations caused by bacterial growth that can lead to vision loss if left untreatled over many years due to their low solubility in water (antimicrobial agents).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] A kind of compound collagen eye drop, its component and the ratio of each component are: in every 100ml compound collagen eye drop, collagen protein content is 50mg; Antibiotic is ofloxacin, and this ofloxacin content It is 300 mg, and the rest is isotonic solution, which is 5% glucose solution.

[0012] The compound collagen eye drops of this example has been tested as follows:

[0013] After more than 10 months of application, 14 cases (23 eyes) of patients with corneal diseases were treated with compound collagen eye drops. Among them: 9 cases of binocular (18 eyes), 5 cases of monocular (5 eyes); 8 cases of male (14 eyes), 6 cases of female (9 eyes); aged from 12 to 70 years old. Among them, there were 3 cases of corneal surgery (5 eyes), 3 cases of corneal injury (5 eyes), 3 cases of punctate keratitis (5 eyes), 2 cases of corneal ulcer (3 eyes), and 1 case of dry eye disease (2 eyes). eye), thermal injury in 1 case (1 eye), eye chemical injury (mild) in 1 case (...

Embodiment 2

[0016] A kind of compound collagen eye drop, its component and the ratio of each component are: in every 100ml compound collagen eye drop, collagen protein content is 100mg; Antibiotic is ofloxacin, and this ofloxacin content It is 350 mg, and the rest is isotonic solution, which is 5% glucose solution.

[0017] The compound collagen eye drops of this example has been tested as follows:

[0018] After more than 10 months of application, 14 cases (23 eyes) of patients with corneal diseases were treated with compound collagen eye drops. Among them: 9 cases of binocular (18 eyes), 5 cases of monocular (5 eyes); 8 cases of male (14 eyes), 6 cases of female (9 eyes), aged 12 to 70 years old. Among them, there were 3 cases of corneal surgery (5 eyes), 3 cases of corneal injury (5 eyes), 3 cases of punctate keratitis (5 eyes), 2 cases of corneal ulcer (3 eyes), and 1 case of dry eye disease (2 eyes). eye), thermal injury in 1 case (1 eye), eye chemical injury (mild) in 1 case (2 ey...

Embodiment 3

[0021] A kind of compound collagen eye drop, its component and the ratio of each component are: in every 100ml compound collagen eye drop, collagen protein content is 150mg; Antibiotic is ofloxacin, and this ofloxacin content It is 400 mg, and the rest is isotonic solution, which is 5% glucose solution.

[0022] The compound collagen eye drops of this example has been tested as follows:

[0023] After more than 10 months of application, 14 cases (23 eyes) of patients with corneal diseases were treated with compound collagen eye drops. Among them: 9 cases of binocular (18 eyes), 5 cases of monocular (5 eyes); 8 cases of male (14 eyes), 6 cases of female (9 eyes); aged from 12 to 70 years old. Among them, there were 3 cases of corneal surgery (5 eyes), 3 cases of corneal injury (5 eyes), 3 cases of punctate keratitis (5 eyes), 2 cases of corneal ulcer (3 eyes), and 1 case of dry eye disease (2 eyes). eye), thermal injury in 1 case (1 eye), eye chemical injury (mild) in 1 case ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a kind of compound collagen protein gutta, which is the mixture of collagen protein and antibiotics. For every 100ml compound collagen gutta, there is 10-500mg collagen protein which is extracted from the tendon, 100-600mg antibiotics which include one or two kinds of the following antibiotics: ofloxacin, alficetin, tenebrimycin, while the rest is the iso-osmia, which is 5% amylaceum solution. The product has three main functions: resist bacteria and inflammation; help to keep the eyeball moist, promote the agglutination and relieve the asthenopia; be used in the treatment of the damage to the cornea, keratohelcosis, keratitis punctata, slight chemical injury to cornea as well as the thermal damage to the cornea; prevent the ophthalmia and relieve the asthenopia; prevent the cohesive property of the collagen from being diluted so as to extend the effective time of the gutta; resist the bacteria as well as promote the agglutination.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner GUANGZHOU TRAUER BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap